General Electric Co.’s (NYSE:GE) healthcare unit followed up the announcement last week of its half-billion-dollar acquisition of cancer diagnostic company Clarient Inc. (NASDAQ:CLRT) with a new deal to acquire Orbotech Ltd. (NASDAQ:ORBK) subsidiary Orbotech Medical Solutions Ltd.
The $9 million cash deal, with up to $5 million in performance-based add-ons, will expand GE Healthcare’s nuclear medicine division with Orbotech’s cadmium zinc telluride detector manufacturing operations.
GE employs Yavne, Israel-based Orbotech’s CZT-based devices in its Alcyone nuclear medicine technology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We believe the future of nuclear medicine lies in the further development of CZT used in our Alcyone technology,” GE Healthcare nuclear medicine manager Nathan Hermony said in prepared remarks.
Alcyone technology is a cardiology imaging platform that combines CZT detectors, focused pin-hole collimation and 3D reconstruction, according to GE, and is available in the company’s Spect and Spect/CT configurations. GE said the devices allow views of cardiac anatomy and functionality with a radiation dosage of up to a four times less than other comparable imaging systems, according to the company.
The companies expect the transaction to close by the first quarter of 2011.
GE Healthcare announced the acquisition of Clarient in a cash deal worth about $587 million.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
